P. falciparum infected erythrocytes
PreclinicalBiologic
P. falciparum infected erythrocytes is one of 45 biologic programs targeting Plasmodium falciparum malaria. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
71 competitors in Plasmodium Falciparum Malaria
#DrugCompanyPhaseTrials
1Lariam
UUnited BioPharma
Approved
Trental
VValidus Pharmaceuticals
Approved
Primaquine
SanofiPhase 2
Artesunate-Amodiaquine
SanofiPhase 3
Amodiaquine-Artesunate (ASAQ)
CCenters for Disease Control and Prevention
Approved
Artesunate
AAmivas Inc.
Phase 2
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Pyronaridine-Artesunate
Medicines for Malaria VenturePhase 3
Atovaquone/proguanil
PfizerPhase 3
Azithromycin IV
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Oxford